These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 28052021)

  • 1. Serum hepatitis B core antibody titer use in screening for significant fibrosis in treatment-naïve patients with chronic hepatitis B.
    Li MR; Zheng HW; Lu JH; Ma SM; Ye LH; Liu ZQ; Zhang HC; Liu YY; Lv Y; Huang Y; Dai EH; Sun DX
    Oncotarget; 2017 Feb; 8(7):11063-11070. PubMed ID: 28052021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients.
    Li MR; Zheng HW; Ma SM; Liu YY; Qie LX; Li JQ; Wang DH; Sun XL; Ren GF; Zheng YH; Wang YL; Dai EH
    J Chin Med Assoc; 2018 Dec; 81(12):1052-1059. PubMed ID: 30143430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients.
    Li MR; Lu JH; Ye LH; Sun XL; Zheng YH; Liu ZQ; Zhang HC; Liu YY; Lv Y; Huang Y; Dai EH
    Medicine (Baltimore); 2016 Aug; 95(34):e4422. PubMed ID: 27559949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection.
    Song LW; Liu PG; Liu CJ; Zhang TY; Cheng XD; Wu HL; Yang HC; Hao XK; Yuan Q; Zhang J; Kao JH; Chen DS; Chen PJ; Xia NS
    Clin Microbiol Infect; 2015 Feb; 21(2):197-203. PubMed ID: 25658546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative HBV Core Antibodies as a Prognostic Marker for HBeAg Seroclearance: A Systematic Review with Meta-Analysis.
    Lazarevic I; Miljanovic D; Banko A; Cupic M; Cirkovic A
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.
    Yuan Q; Song LW; Cavallone D; Moriconi F; Cherubini B; Colombatto P; Oliveri F; Coco BA; Ricco G; Bonino F; Shih JW; Xia NS; Brunetto MR
    PLoS One; 2015; 10(6):e0130209. PubMed ID: 26115521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naïve, e antigen-positive patients.
    Martinot-Peignoux M; Carvalho-Filho R; Lapalus M; Netto-Cardoso AC; Lada O; Batrla R; Krause F; Asselah T; Marcellin P
    J Hepatol; 2013 Jun; 58(6):1089-95. PubMed ID: 23369792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare.
    Han Y; Tang Q; Zhu W; Zhang X; You L
    J Gastroenterol Hepatol; 2008 Nov; 23(11):1728-33. PubMed ID: 18823435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.
    Hou FQ; Song LW; Yuan Q; Fang LL; Ge SX; Zhang J; Sheng JF; Xie DY; Shang J; Wu SH; Sun YT; Wei SF; Wang MR; Wan MB; Jia JD; Luo GH; Tang H; Li SC; Niu JQ; Zhou WD; Sun L; Xia NS; Wang GQ
    Theranostics; 2015; 5(3):218-26. PubMed ID: 25553110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of anti-HBc quantification in hepatitis B virus related acute-on-chronic liver failure.
    Li J; Gong QM; Xie PL; Lin JY; Chen J; Wei D; Yu DM; Han Y; Zhang XX
    J Gastroenterol Hepatol; 2021 May; 36(5):1291-1299. PubMed ID: 33091955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
    Dezanet LNC; Maylin S; Gabassi A; Rougier H; Miailhes P; Lascoux-Combe C; Chas J; Girard PM; Delaugerre C; Lacombe K; Boyd A
    J Infect Dis; 2020 May; 221(11):1826-1837. PubMed ID: 31960918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA.
    Yao K; Wang J; Wang L; Xia J; Yan X; Wu W; Liu J; Wang L; Yin S; Tong X; Ding W; Huang R; Wu C
    J Med Virol; 2022 Feb; 94(2):659-666. PubMed ID: 34499353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.
    Zhao XA; Wang J; Liu J; Chen G; Yan X; Jia B; Yang Y; Liu Y; Gu D; Zhang Z; Xiang X; Huang R; Wu C
    Antiviral Res; 2021 Sep; 193():105146. PubMed ID: 34314774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.
    Hu J; Zhang X; Gu J; Yang M; Zhang X; Zhao H; Li L
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):817-823. PubMed ID: 30543572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum qAnti-HBc combined with ALT and HBsAg predicts significant hepatic inflammation in HBeAg-positive immune active patients.
    Wang X; Gao X; Wu R; Chi X; Xu H; Guan Y; Jin Q; Niu J
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1806-1814. PubMed ID: 35509262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced HBsAg synthesis correlates with increased severity of fibrosis in chronic hepatitis B patients.
    Hong MZ; Huang WQ; Min F; Xu JC; Lin Z; Fang KN; Pan JS
    PLoS One; 2014; 9(1):e87344. PubMed ID: 24498079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between serum platelet-derived growth factor BB and degree of liver damage, fibrosis and hepatitis B e antigen (HBeAg) status in CHB patients.
    Diang XC; Ma LN; Li YF; Liu XY; Zhang X; Liu JY; Sheng YJ; Zhang DZ; Hu HD; Ren H
    Hepatogastroenterology; 2012; 59(120):2357-60. PubMed ID: 22688015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of hepatic inflammation in chronic hepatitis B patients with a random forest-backward feature elimination algorithm.
    Zhou JY; Song LW; Yuan R; Lu XP; Wang GQ
    World J Gastroenterol; 2021 Jun; 27(21):2910-2920. PubMed ID: 34135561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies.
    Xiang Y; Chen P; Xia JR; Zhang LP
    Genet Mol Res; 2017 Feb; 16(1):. PubMed ID: 28252163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in basal core promoter is associated with significant fibrosis in both HBeAg positive and negative treatment-naïve chronic hepatitis B.
    Yan LB; Zhu X; Bai L; Tang XQ; Du LY; Chen EQ; Liang LB; Tang H
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):296-302. PubMed ID: 27988305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.